Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells

Published:2016-09-29 Issue:13 Volume:128 Page:1711-1722
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Faitschuk Elena¹²,Hombach Andreas A.¹²,Frenzel Lukas P.²³,Wendtner Clemens-Martin²⁴,Abken Hinrich¹²

Affiliation:

1. Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany;

2. Department I Internal Medicine, University Hospital Cologne, Cologne, Germany;

3. Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; and

4. Klinikum Schwabing, Munich, Germany

Abstract

Key Points FcμR is a more selective target for the CAR T-cell therapy of CLL compared with currently used targets, including CD19.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/13/1711/1395609/1711.pdf

Reference35 articles.

1. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.;Sorror;J Clin Oncol,2008

2. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?;Dreger;Blood,2014

3. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.;Hillmen;Lancet,2015

4. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.;Goede;N Engl J Med,2014

5. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.;Fischer;J Clin Oncol,2012

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them;Cancer Drug Resistance;2024-05-14

2. Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma;Frontiers in Oncology;2024-04-22

3. Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia;OncoTargets and Therapy;2024-03

4. Chimeric Antigen Receptor T-cell Therapy for Chronic Lymphocytic Leukemia: What is the supporting evidence so far?;Clinical Hematology International;2023-11-28

5. Broadening the horizon: potential applications of CAR-T cells beyond current indications;Frontiers in Immunology;2023-11-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3